All In Biotech

Drug Trial Radar · NCT05711394

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 Years of Age.

Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 450 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

450

Planned (sponsor's estimate)

Start

May 1, 2023

Primary completion

Mar 2028

Study completion May 2028

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Feb 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. A number of treatments are available for adults with migraine but there are limited approved treatments available for pediatric participants. The main goal of the study is to evaluate the safety and efficacy (how well treatment works) of a low-dose and high-dose of atogepant in pediatric participants between the ages of 6 and 17. Atogepant is a medicine currently approved to treat adults with migraine (0 to 14 migraine days per month) and is being studied in pediatric participants between the ages of 6 and 17 with a history of episodic migraine. This is a Phase 3, randomized, double-blind study of atogepant in participants with a history of episodic migraine with an open-label pharmacokinetic substudy. Eligible participants will be randomized into 6 different groups. Participants between the ages of 12 and 17 will be randomized to receive placebo, low-dose atogepant, or high-dose atogepant for 12 weeks. Participants between the ages of 6 and 11 will also be randomized to receive placebo, low-dose atogepant, or high-dose atogepant for 12 weeks. The specific atogepant doses to be used in participants between the ages of 6 and 11 will be determined after the PK substudy is complete. Around 450 participants will be enrolled in approximately 100 sites worldwide. Placebo, low-dose atogepant, and high-dose atogepant are given as a tablet to take by mouth once a day. At the end of Week 12, participants will either undergo a follow-up visit 4 weeks after last study treatment or join an extension study where they can continue to receive atogepant for another 52 weeks. There may be a bigger responsibility for participants in this study. Participants will attend regular visits during the study at a hospital or clinic. The effects of treatment will be checked by medical assessments, blood tests, checking for side effects, and completing questionnaires.

Conditions

  • Episodic Migraine

Interventions

  • AtogepantDrug

    Oral Tablet

  • Placebo-Matching AtogepantDrug

    Oral Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Mean Monthly Migraine DaysTime frame: Baseline (Week 0) through Week 12
  2. Number of Participants Experiencing Adverse EventsTime frame: Baseline (Week 0) through Week 16

Locations

98 sites in 16 countries. Site status is shown where the registry gives one.

  • Rehabilitation & Neurological Services /ID# 248517

    Huntsville, Alabama · Recruiting

  • The Center for Clinical Trials - Saraland /ID# 271604

    Saraland, Alabama · Recruiting

  • Preferred Research Partners /ID# 249729

    Little Rock, Arkansas · Recruiting

  • Preferred Research Partners /ID# 270406

    Little Rock, Arkansas · Completed

  • Advanced Research Center /ID# 251381

    Anaheim, California · Recruiting

  • Alliance for Research Alliance for Wellness /ID# 248521

    Long Beach, California · Recruiting

  • Excell Research, Inc /ID# 247532

    Oceanside, California · Completed

  • Lumos Clinical Research Center /ID# 249731

    San Jose, California · Recruiting

  • Sunwise Clinical Research /ID# 248529

    Walnut Creek, California · Recruiting

  • Advanced Neurosciences Research, LLC /ID# 247592

    Fort Collins, Colorado · Completed

  • Northwest Florida Clinical Research Group, LLC /ID# 251382

    Gulf Breeze, Florida · Completed

  • Advanced Research Institute of Miami /ID# 248539

    Homestead, Florida · Completed

  • My Preferred Research LLC /ID# 249720

    Miami, Florida · Recruiting

  • FWD Clinical Research - Spring Hill /ID# 248525

    Spring Hill, Florida · Completed

  • Coastal Georgia Child Neurology /ID# 249733

    Brunswick, Georgia · Recruiting

  • Deaconess Clinic - Gateway Health Center /ID# 247589

    Newburgh, Indiana · Recruiting

  • College Park Family Care Center Overland Park /ID# 249734

    Overland Park, Kansas · Completed

  • Michigan Headache & Neurological Institute (MHNI) /ID# 247468

    Ann Arbor, Michigan · Recruiting

  • Proven Endpoints LLC /ID# 258066

    Ridgeland, Mississippi · Recruiting

  • Cognitive Clinical Trials (CCT) - Papillion /ID# 248536

    Papillion, Nebraska · Completed

  • Goryeb Childrens Hospital /ID# 249724

    Morristown, New Jersey · Recruiting

  • Dent Neurologic Institute - Amherst /ID# 248534

    Amherst, New York · Recruiting

  • Modern Migraine MD /ID# 258074

    New York, New York · Completed

  • Headache Wellness Center /ID# 251018

    Greensboro, North Carolina · Recruiting

  • Patient Priority Clinical Sites, LLC /ID# 247535

    Cincinnati, Ohio · Recruiting

  • Cincinnati Childrens Hospital Medical Center /ID# 258070

    Cincinnati, Ohio · Recruiting

  • CincyScience /ID# 249726

    West Chester, Ohio · Completed

  • Lynn Institute of Oklahoma City /ID# 247600

    Oklahoma City, Oklahoma · Completed

  • Children's Hospital of Philadelphia - Main /ID# 258071

    Philadelphia, Pennsylvania · Recruiting

  • Le Bonheur Children's Hospital /ID# 261084

    Memphis, Tennessee · Completed

  • Access Clinical Trials, Inc. /ID# 248532

    Nashville, Tennessee · Recruiting

  • UT Health Austin at Dell Children's Neurology Clinic /ID# 264082

    Austin, Texas · Recruiting

  • FutureSearch Trials of Neurology /ID# 247470

    Austin, Texas · Completed

  • 3A Research - East El Paso /ID# 248516

    El Paso, Texas · Completed

  • Earle Research /ID# 248501

    Friendswood, Texas · Recruiting

  • Family Psychiatry of The Woodlands /ID# 249727

    The Woodlands, Texas · Completed

  • ClinPoint Trials /ID# 248540

    Waxahachie, Texas · Recruiting

  • Pantheon Clinical Research /ID# 251601

    Bountiful, Utah · Recruiting

  • Alpine Research Organization - Clinton /ID# 276497

    Clinton, Utah · Recruiting

  • Highland Clinical Research /ID# 247590

    Salt Lake City, Utah · Recruiting

Showing 40 of 98 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.